<DOC>
	<DOC>NCT00544934</DOC>
	<brief_summary>A dose-ranging study evaluating safety, metabolism and therapeutic dosing of three multiple dose levels of GLY-230 in healthy and diabetic subjects</brief_summary>
	<brief_title>Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Nondiabetic and diabetic men age 1855, engative drug screen, normal EKG, clinical chemistries. hematology parameters, HbA1c 7.5% if diabetic, give written informed consent Sctive concomitant serious medical or surgical disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>